Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SURPASS ET

The most promising emerging therapies and developments in PV and ET
1:56
The most promising emerging therapies and developments in PV and ET
Lucia Masarova • 2 Sep 2025
What's new in essential thrombocythemia in 2025?
1:36
What's new in essential thrombocythemia in 2025?
Alexander Coltoff • 27 Aug 2025
Recent updates and emerging therapies in essential thrombocythemia
1:45
Recent updates and emerging therapies in essential thrombocythemia
Olatoyosi Odenike • 23 Aug 2025
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
1:21
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
Ruben Mesa • 19 Jun 2025
Recent advances and trial updates in MPNs: insights from EHA 2025
7:00
Recent advances and trial updates in MPNs: insights from EHA 2025
Prithviraj Bose • 15 Jun 2025
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
1:52
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
Lucia Masarova • 14 Jun 2025
Practice-changing findings in MPNs from ASCO 2025
0:57
Practice-changing findings in MPNs from ASCO 2025
Andrew Kuykendall • 3 Jun 2025
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
1:28
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
Lucia Masarova • 10 Oct 2023
Current treatment approaches in ET and an insight into the SURPASS-ET trial
1:45
Current treatment approaches in ET and an insight into the SURPASS-ET trial
Srdan Verstovsek • 15 Nov 2022
The SURPASS-ET study: evaluating novel treatment approaches in ET
2:05
The SURPASS-ET study: evaluating novel treatment approaches in ET
Srdan Verstovsek • 8 Sep 2022
Unmet needs and therapeutic strategies in essential thrombocythemia
3:29
Unmet needs and therapeutic strategies in essential thrombocythemia
Srdan Verstovsek • 7 Jul 2022
Upcoming trials and novel agents in MPNs
1:44
Upcoming trials and novel agents in MPNs
Ruben Mesa • 25 May 2022
Advances in the science and treatment of MPNs
1:49
Advances in the science and treatment of MPNs
Ruben Mesa • 25 Apr 2022
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
1:59
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
Ruben Mesa • 24 Jan 2022
SURPASS ET: P1101 in essential thrombocythemia
1:57
SURPASS ET: P1101 in essential thrombocythemia
Harinder Gill • 11 Dec 2021
The content of VJHemOnc is intended for healthcare professionals